Dr. Nicolas G. Bazan of the Louisiana State University in New Orleans, and associates at LSU and Brigham & Women’s Hospital in Boston, studied how docosahexaenoic acid (DHA), an omega-3 fatty acid, affects the human brain.
Dr. Ross Andel of the University of South Florida in Tampa, and team, studied 10,079 adults who were listed in the Swedish Twin Registry.
Patients with multiple sclerosis showed significant improvement in their depression during 16 weeks of telephone-administered psychotherapy treatment, according to an article in the September issue of the Archives of General Psychiatry, one of the JAMA/Archives journals.
New research published in the August 2005 issue of the American Journal of Psychiatry indicates that methamphetamine abuse and HIV infection cause significant alterations in the size of certain brain structures, and in both cases the changes may be associated with impaired cognitive functions, such as difficulties in learning new information, solving problems, maintaining attention and quickly processing information.
Recent su icide attempters treated with cognitive therapy were 50 percent less likely to try to k ill themselves again within 18 months than those who did not receive the therapy, report researchers supported by the National Institutes of Health?s (NIH) National Institute of Mental Health (NIMH) and the Center for Disease Control and Prevention (CDC).
A 10-item smell identification test seems to be useful for finding out if people with mild mental impairment are at increased risk of developing Alzheimer’s disease, according to investigators.
The use of statins and other lipid-lowering agents by older adults was not associated with a reduced risk of Alzheimer’s disease or other types of dementia, according to a study in the July issue of the Archives of Neurology, one of the JAMA/Archives journals.
Efforts to define the abnormally activated areas in the brains of people with bipolar disorder could lead to new drug treatments and better coping strategies, investigators reported at the International Conference on Bipolar Disorder in Pittsburgh.
Many of the medications widely used to manage chronic insomnia have not yet been rigorously evaluated for long-term use, according to an independent scientific panel convened this week by the National Institutes of Health. This is a critical consideration because for many patients, insomnia can persist for decades. The panel also stressed that many chronic insomnia sufferers could benefit from currently underused behavioral and cognitive therapies.
People who are overweight or obese can use behavioural and cognitive-behavioural strategies to help lose weight.